PhRMA

Across the country, America’s biopharmaceutical companies are delivering on a $500 billion commitment to expand U.S. manufacturing and R&D. New facilities are breaking ground, hundreds of thousands of high-quality jobs are being created and entire communities are benefiting from the growth of this innovation ecosystem. These investments aren’t just about factories and labs. They’re about strengthening America’s ability to discover and make the next generation of cures, right here at home. I am proud to see this commitment taking shape and to work alongside the people bringing it to life. Learn more about the projects driving progress and opportunity for patients and for our country.

There’s a lot of conversation about how to lower drug costs in this country. So let’s look at a policy that was supposed to do just that: the price-setting provisions in the Inflation Reduction Act. Three years later, it serves as a cautionary tale about the reality of price setting. The policy is undermining medical progress people are counting on. Since the IRA took effect, investment in early-stage small-molecule medicines has dropped nearly 70%, and post-approval cancer research has fallen more than 40%. That’s not a future any patient should be asked to accept. Meanwhile, the real drivers of patient costs remain untouched: middlemen who take half of every dollar spent on medicines. These entities include PBMs, insurers and 340B hospitals who don’t make medicines, and despite price setting, they continue to determine what patients pay and which treatments they can access. This is a uniquely American issue that drives up costs for patients. Patients deserve lower costs and continued breakthroughs. Reining in middlemen is how we deliver both. Dive deeper on the promises vs the reality of price setting in PhRMA’s latest blog:

Hepatitis B is serious — but preventable with early protection. Chief Medical Officer Michael Ybarra, MD breaks down why the hepatitis B vaccine shortly after birth is one of the most effective ways to protect newborns from lifelong liver disease. Learn more from Dr. Ybarra. https://lnkd.in/etJ9cRum

The recommended vaccine schedule isn’t arbitrary—it reflects years of research on when kids are most vulnerable to serious illness. Combination vaccines help families stay on track with fewer appointments and fewer needles. Learn more about the evidence behind vaccine schedules from CMO Michael Ybarra, MD phrma.org/vaccines

Too many Americans are paying more for their medicines and facing delays because insurers and PBMs can add markups, deny coverage or require patients to try and fail other treatments before getting what their doctors prescribed. Direct purchase programs offer a better option. They allow patients to buy directly from manufacturers, with transparent pricing that can reduce costs and help people access their medicines more quickly. And starting in January 2026, AmericasMedicines.com will serve as a trusted site where patients, caregivers and employers can explore available direct purchase programs and patient support resources. The biopharmaceutical industry is doing our part. Now, policymakers must fix the system that lets middlemen drive up costs and delay access to care. Visit America’s Medicines to learn more: https://lnkd.in/evEbDxTn

Vaccines protect us every day — but many people still have important questions. Hear from our Chief Medical Officer, Dr. Mike Ybarra, as he breaks down what you need to know about how vaccines work and why they matter. https://lnkd.in/eTAy4z9F